多西他赛单药用于晚期食管鳞癌二线治疗的疗效分析  

Efficacy of Single Agent Docetaxel as Second-line Chemotherapy in the Treatment for Advanced Esophageal Squamous Cell Cancer

作　　者：洪国标[1] 肖建军[1] 

机构地区：[1]绍兴第二医院,浙江绍兴312000

出　　处：《肿瘤学杂志》2015年第6期499-503,共5页Journal of Chinese Oncology

摘　　要：[目的]探讨多西他赛在晚期食管鳞癌患者二线治疗中的疗效及不良反应。[方法]回顾性分析85例晚期食管鳞癌患者,所有患者均为一线治疗进展后采用二线多西他赛治疗。Kaplan-Meier法进行生存分析。Cox法对影响患者预后的因素进行多因素分析。[结果]患者中位无进展生存期为3.5个月,中位生存期为5.5个月。一线化疗达到部分缓解的患者多西他赛治疗疗效优于一线治疗后稳定及进展的患者（4.0个月vs 3.2个月,P=0.015）。多数患者能够耐受不良反应,发生Ⅲ~Ⅳ度不良反应的患者比例为25.8%。[结论]多西他赛在二线食管鳞癌患者中有一定的疗效。一线治疗中疗效好的患者采用多西他赛二线治疗疗效较好。[Purpose] To investigate the clinical efficacy and toxicity of advanced esophageal squamous cell carcinoma who received second-line docetaxel chemotherapy after failure of firstline treatment. [Methods] We retrospectively reviewed eighty-five patients who received secondline docetaxel chemotherapy for advanced esophageal squamous cell carcinoma. Survival curves were plotted using the Kaplan-Meier method. The Cox proportional hazard model was used for multivariate analysis. [Results] The progression-free survival（PFS） and overall survival（OS） were3.5 and 5.5 months,respectively. Response to first-line chemotherapy was a favorable prognostic factor for PFS compare with non-response patients（4.0 months vs. 3.2 months,P=0.015）. Toxicities of the docetaxel regimen were manageable and the frequency of grade 3/4 toxicities was 25.8%.[Conclusions] Patients with docetaxel second-line treatment obtain a moderate PFS advantage in advanced ESCC. Response to first-line chemotherapy is a favorable prognostic factor for PFS of second-line chemotherapy in advanced esophageal squamous cell carcinoma.

关 键 词：食管肿瘤 鳞状细胞 多西他赛 化学药物疗法 

分 类 号：R735.1[医药卫生—肿瘤]